Development of in vitro models of Parkinson's and
Alzheimer's diseases
Elucidation of the mechanicistic basis of neuroprotective
potential of natural compounds
Development of in vivo models of neurodegeneration
Development of in vitro models of Parkinson's and
Alzheimer's diseases in order to study neurodegenerative events
induced by specific neurotoxins (6-OHDA and β-amiloid peptide) in
neuronal (SH-SY5Y) and glial (C6) cells. Identification of cellular
and molecular targets involved in neuronal death.
Evaluation of neuroprotective activity of new compounds using
in vitro models of Parkinson's and Alzheimer's diseases,
in terms of capability to prevent and rescue the progression of
apoptotic and necrotic neuronal death, induced by neurotoxins.
Elucidation of neurodegenerative events in in vivo
models of Parkinson's and Alzheimer's diseases. Evaluation of
the capability of new agents to counteract crucial biological
events involved in neuronal death in specific areas, such as
hippocampus and substantia nigra.
